Study	Naltrexone Events	Naltrexone Total	Placebo Events	Placebo Total	RR	95%−CI
High Risk of Bias						
Anton 2018	1	76	0	76	3.00	[0.12; 72.49]
Balldin 2003	0	56	1	62	0.37	[0.02; 8.87]
Castro 2004	0	35	2	36	0.21	[0.01; 4.13]
Foa 2013	5	82	7	83	0.72	[0.24; 2.19]
Garbutt 2016	0	40	1	40	0.33	[0.01; 7.94]
Greenway 2009a	1	60	0	59	2.95	[0.12; 70.99]
Greenway 2009a bupropion	0	60	2	59	0.20	[0.01; 4.01]
Kampman 2015 NTX	6	40	11	42	0.57	[0.23; 1.40]
Kampman 2015 NTX modafinil	11	45	6	37	1.51	[0.62; 3.69]
King 2012	2	168	2	165	0.98	[0.14; 6.89]
Kranzler 2009 targeted	2	38	0	39	5.13	[0.25; 103.42]
Mooney 2016	0	61	1	60	0.33	[0.01; 7.89]
Morris 2001	8	55	6	56	1.36	[0.50; 3.66]
O'Malley 2007	0	57	2	50	0.18	[0.01; 3.57]
Peters 2015	12	54	17	56	0.73	[0.39; 1.38]
Petrakis 2004	3	16	1	15	2.81	[0.33; 24.16]
Petrakis 2005 NTX	1	59	4	64	0.27	[0.03; 2.36]
Petrakis 2005 NTX/disulfiram	3	65	6	66	0.51	[0.13; 1.94]
Petrakis 2012 NTX/paroxetine	0	22	2	20	0.18	[0.01; 3.58]
Pettinati 2010 NTX	13	49	11	39	0.94	[0.47; 1.86]
Pettinati 2010 NTX/sertraline	5	42	15	40	0.32	[0.13; 0.79]
Schmitz 2014	1	16	1	18	1.12	[0.08; 16.55]
Toll 2010a	2	87	2	85	0.98	[0.14; 6.78]
Wang 2018	8	96	5	98	1.63	[0.55; 4.82]
Fixed effect model		**1379**		**1365**	**0.77**	**[0.59; 1.00]**
Random effects model					**0.80**	**[0.61; 1.05]**
Heterogeneity: I^2 = 0%, p = 0.67						
Low Risk of Bias						
Anton 2006	10	309	8	309	1.25	[0.50; 3.12]
Anton 2006	17	305	17	303	0.99	[0.52; 1.91]
Cook 2017	1	12	0	7	1.80	[0.08; 38.77]
Kahler 2017	0	75	3	75	0.14	[0.01; 2.72]
O'Malley 2006 NTX 50mg	2	99	0	32	1.63	[0.08; 33.15]
O'Malley 2008	4	34	4	34	1.00	[0.27; 3.68]
Oslin 2015	1	111	4	110	0.25	[0.03; 2.18]
Fixed effect model		**945**		**870**	**0.93**	**[0.59; 1.48]**
Random effects model					**0.97**	**[0.61; 1.54]**
Heterogeneity: I^2 = 0%, p = 0.71						
Fixed effect model		**2324**		**2235**	**0.81**	**[0.64; 1.02]**
Random effects model					**0.84**	**[0.66; 1.06]**
Heterogeneity: I^2 = 0%, p = 0.78